Life Science Integrates launches new Bio Integrates to address the biggest challenges impacting the pharma and biotech sector
London, UK, 21st March 2019 / Sciad Newswire / Inspired by the success of Pharma Integrates, Life Science Integrates has introduced the new Bio Integrates conference, to be held at the Grange Tower Bridge Hotel, London, on the 22ndMay 2019. This one-day gathering of start-ups, SMEs and emerging companies will provide a platform to discuss the major challenges impacting the pharma and biotech sector. Addressing topics such as precision medicine, cell and gene therapy, artificial intelligence, in silico and virtual trials, the focus will be on collaboration.
The event will comprise roundtable discussions, breakout sessions and keynote presentations, updating delegates on industry-wide initiatives, alternative business models and innovative deal structures.
Bio Integrates will bring together experts from the biotech and wider stakeholder community to examine and address the drivers and hurdles of today and resolve the critical business issues of tomorrow. Speakers will include:
Melanie Lee | Chief Executive Officer, LifeArc
Mary Kerr | Chief Executive Officer, KaNDy Therapeutics & NeRRe Therapeutics
Jane Dancer | Chief Business Officer, F-star
Julian Hanak | Senior Vice President & Global Head CMC, Nightstar Therapeutics
Martin O’Kane | Head of Clinical Trials Unit, MHRA
Tim Luker | Senior Director External Innovation, Eli Lilly
For further information, contact:
Juliette Craggs, PR & Digital Executive
T: +44 (0)20 7470 8801
Notes to Editors
About Life Science Integrates
Our mission is to bring together the top leaders in their fields, to share insights into the current state of their industries, define future strategies and to build successful alliances.
We produce debate-led events which have helped to define the future provision of pharmaceuticals and healthcare services.
For the past seven years our renowned Pharma Integrates event has attracted speakers from across the world, with participation from leading pharmaceutical companies, disruptive entrants and start-ups, regulators and academics; these conversations have shaped the industry today and for the future.